SCHEMBL4867393

SCHEMBL4867393

[O]C1(C(=O)O)CCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7677084 0.93
SCHEMBL36310 0.90 CYP2C19 (0.44)
SCHEMBL11006083 0.88 CYP2C19 (0.42)
SCHEMBL198365 0.86
SCHEMBL5402819 0.71
SCHEMBL8907359 0.69 FFAR3 (0.40)
SCHEMBL127199 0.69 FFAR3 (0.40)
Hydrochloric Acid SCHEMBL627730 0.69 FFAR3 (0.40)
SCHEMBL20679 0.69 FFAR3 (0.40)
Hydrochloric Acid SCHEMBL2294530 0.69 FFAR3 (0.40)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 223 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3870295-B1 NOVEL TRICYCLIC COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE HOFFMANN LA ROCHE (CH) 2023-03-08 EP claimed
US-20220402897-A1 CHROMEN-4-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE HOFFMANN-LA ROCHE INC. (US) 2022-12-22 US claimed
US-20210387996-A1 TRICYCLIC COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE HOFFMANN-LA ROCHE INC. (US) 2021-12-16 US claimed
CN-112888480-A Novel tricyclic compounds for the treatment and prevention of hepatitis b virus diseases 豪夫迈·罗氏有限公司 2021-06-01 CN claimed
CN-112839714-A Chromen-4-one derivatives for the treatment and prevention of hepatitis B virus diseases 豪夫迈·罗氏有限公司 2021-05-25 CN claimed
WO-2020079106-A1 CHROMEN-4-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2020-04-23 WO claimed
US-7317026-B2 Sleep disorders; side effect reduction ; antihistamine antagonist HYPNION, INC. (US) 2008-01-08 US claimed
US-20040142972-A1 CNS target modulators HYPNION, INC. 2004-07-22 US claimed
US-11993591-B2 Chromen-4-one derivatives for the treatment and prophylaxis of hepatitis B virus disease HOFFMANN-LA ROCHE INC. (US) 2024-05-28 US disclosed
US-11912721-B2 Fused pentacyclic imidazole derivatives UCB Biopharma SRL (BE) 2024-02-27 US disclosed
EP-3870295-B1 NOVEL TRICYCLIC COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE HOFFMANN LA ROCHE (CH) 2023-03-08 EP disclosed
US-20220402897-A1 CHROMEN-4-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE HOFFMANN-LA ROCHE INC. (US) 2022-12-22 US disclosed
CN-114072392-A Luminescent compound or salt thereof, and polarized light-emitting element, polarized light-emitting panel, and display device each containing the same 日本化药株式会社 2022-02-18 CN disclosed
CN-109195968-B Fused pentacyclic imidazole derivatives as modulators of TNF activity UCB生物制药私人有限公司 2022-02-11 CN disclosed
US-6130225-A Substituted p-trifluoromethylphenyluracils BAYER AKTIENGESELLSCHAFT (DE) 2000-10-10 US disclosed
EP-0923562-A1 SUBSTITUTED P-TRIFLUOROMETHYLPHENYLURACILS BAYER AG (DE) 1999-06-23 EP disclosed
WO-1998006706-A1 SUBSTITUTED P-TRIFLUOROMETHYLPHENYLURACILS BAYER AKTIENGESELLSCHAFT (DE) 1998-02-19 WO disclosed
EP-0341910-B1 Cephalosporins, process for their preparation, intermediates and pharmaceutical compositions ICI PLC (GB) 1994-11-23 EP disclosed
US-5064824-A CEPHALOSPORIN COMPOUNDS IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1991-11-12 US disclosed
EP-0341910-A2 Cephalosporins, process for their preparation, intermediates and pharmaceutical compositions ZENECA LIMITED (GB) 1989-11-15 EP disclosed